Pathological Complete Response
Tryphaena
•
Regardless of chemotherapy chosen, the combination of pertuzumab with trastuzumab
in the neoadjuvant setting resulted in high pCR rates
Pathologic complete response (%)
FEC+H+P x3
T+H+P x3
(n = 73)
FEC x3
T+H+P x3
(n = 75)
TCH+P x6
(n = 77)
50.7
45.3
51.9
ypT0/is
ypT0 ypN0
61.6
66.2
57.3
ypT0/is, no invasive tumor residues in the breast; ypT0 ypN0, no invasive and noninvasive tumor residues in the breast and lymph nodes at surgery;
FEC, 5-fluorouracil, epirubicin, cyclophosphamide; H, trastuzumab; P, pertuzumab; T, docetaxel; C, carboplatin
56.2
54.7
63.6
ypT0/is ypN0
Schneeweiss et al. Ann of Oncology 2013;
